

Replacement Page 25

Table 6. Demographic and Baseline Disease Characteristics: Studies 437 and 438

	Study GS-98-437 HBeAg+ Chronic HBV Infection		Study GS-98-438 HBeAg-/anti-HBe/HBV DNA HBV Infection	
	Placebo N = 167	Adefovir Dipivoxil 10 mg N = 171	Placebo N = 61	Adefovir Dipivoxil 10 mg N = 123
Age (years)				
Median	35	32	45	46
Q1 to Q3	28 to 43	25 to 42	39 to 53	40 to 53
Gender				
Males	119 (71%)	130 (76%)	50 (82%)	102 (83%)
Females	48 (29%)	41 (24%)	11 (18%)	21 (17%)
Race				
Caucasian	60 (36%)	60 (35%)	40 (66%)	82 (67%)
Black	3 (2%)	8 (5%)	1 (2%)	5 (4%)
Asian	101 (60%)	102 (60%)	20 (33%)	36 (29%)
Other	3 (2%)	1 (< 1 %)	0%	0%
Prior HBV Therapy *				
Interferon- α	35 (21%)	42 (25%)	28 (46%)	48 (39%)
Lamivudine	3 (2%)	1 (<1%)	4 (7%)	10 (8%)
Other	15 (9%)	17 (10%)	7 (11%)	7 (6%)
Total Knodell HAI Score				
Median	10	9.5	9	10
Q1 to Q3	8 to 12	8 to 11	6 to 11	8 to 12
Knodell Necro-inflammatory Score				
Median	8	7	7	8
Q1 to Q3	7 to 10	7 to 9	5 to 10	7 to 10
Knodell Fibrosis Score				
Median	1	1	1	1
Q1 to Q3	1 to 3	1 to 3	1 to 3	1 to 3
Cirrhosis	13 (8%)	12 (7%)	6 (10%)	14 (11%)
HBV-DNA (log ₁₀ copies/mL)				
Median	8.33	8.40	7.05	7.10
Q1 to Q3	7.5 to 8.76	7.69 to 8.87	6.24 to 7.67	6.35 to 7.53
ALT (IU/L)				
Median	94	95	100	93
Q1 to Q3	69 to 159	65 to 165	72 to 161	69 to 165
ALT (x ULN)				
Median	2.4	2.3	2.4	2.3
Q1 to Q3	1.7 to 3.9	1.6 to 3.9	1.7 to 3.9	1.7 to 3.8

* Prior HBV-medications for the purpose of this analysis was classed as interferon alpha only as the number of patients taking other prior medications was low per protocol exclusion criteria.

Source: GS-98-437 ICSR, Table 11-2, 11-3, 11-4; GS-98-438 ICSR, Table 11-2, 11-3